LN019 / Shandong Luning Pharmaceutical - LARVOL DELTA

LN019, a novel HER2-targeting affibody-drug conjugate, demonstrates superior antitumor efficacy compared to T-DXd in xenograft models (AACR 2026) - "Consequently,LN019 represents a promising next-generation therapeutic candidate for HER2-overexpressing malignancies , potentially offering an improved safety profile and efficacy in solid tumors where tissue penetration is a limiting factor. This work was supported by the Natural Science Foundation of Shanghai (25ZR1402262), the State Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Jiao Tong University (sklscbs202547)"

Late-breaking abstract • Preclinical • Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • HER-2